INC Research/inVentiv Health (Nasdaq: INCR) today announced it has changed its brand identity to Syneos Health, Inc., effective January 4, 2018. More than 21,000 of the top minds in clinical and commercial development are now united under this singular brand, signifying the culmination of a thoughtful merger combining industry-leading Contract Research Organization (CRO) and Contract Commercial Organization (CCO) capabilities. Purpose-built for modern biopharmaceutical market realities, Syneos Health is the only fully integrated, end-to-end biopharmaceutical solutions organization.
The word Syneos (pronounced SIN-ee-ohs) communicates the value of synchronizing clinical and commercial capabilities to accelerate customer performance. Syneos Health solutions are fully integrated – sharing knowledge, data and insights – to deliver better processes and smarter practices to speed the delivery of biopharmaceutical therapies to market.
The name is also derived from “neo,” signaling a new approach to problem-solving and a new biopharmaceutical solutions category for the healthcare workforce. The company logo communicates the seamless integration of multidisciplinary services, and the color palette is a vibrant orange spectrum, embodying the company’s bold vision.
“Syneos Health fully expresses our value proposition – that is, our ability to deliver integrated end-to-end solutions and create new paths for our customers to develop and commercialize their therapies,” said Alistair Macdonald, Chief Executive Officer of Syneos Health. “Unlike traditional CROs and commercialization businesses, we are knocking down walls and enabling clinical and commercial experts to work in sync by using the latest technologies, advanced business practices and the advantages of scale. Our Biopharmaceutical Acceleration Model is unique to the industry, and from this ambitious vision, Syneos Health was born.”
The company’s highly integrated platform leverages a powerful combination of clinical and commercial solutions. For example, behavioral insights are leveraged to accelerate clinical trial recruitment, and therapeutic know-how infuses multi-channel commercial programs to better engage increasingly hard-to-reach stakeholders. All of these solutions are designed to improve the likelihood of launch success.
Syneos Health tapped its own industry-leading branding agency, Addison Whitney, to create the company’s new identity. Addison Whitney creates brand identities for corporations, employer brands, consumer brands and biopharmaceutical therapies, including half of the top 200 medicines approved and launched in the last 10 years.
Macdonald continued, “As commercialization experts, we understand the importance a strong brand plays in creating differentiation, conversion and loyalty. Our new identity reinforces our fully integrated business model, positions Syneos Health as a high-value solutions partner, and is designed to attract and retain top talent committed to shortening the distance from lab to lifeTM.”
In connection with the name change, Syneos Health common shares are expected to trade on the Nasdaq Global Select Market under the new ticker symbol “SYNH” by January 9, 2018. Until then, Syneos Health will continue to be listed under INC Research Holdings, Inc. and the symbol “INCR.”
